News

People with type 2 diabetes who use DPP4 inhibitors to manage their disease do not seem to have a higher risk of developing angioedema compared with those taking other oral antidiabetic medications. That’s according to a study in South Korea, which found that new cases of angioedema occurred at…

The U.S. Food and Drug Administration (FDA) has approved sebetralstat for the on-demand treatment of swelling attacks in adults and children, ages 12 and older, with hereditary angioedema (HAE), its developer Kalvista Pharmaceuticals announced. Sebetralstat will be sold under the brand name Ekterly, and is the first…

A woman in her 30s who experienced recurrent, nonspecific gastrointestinal symptoms was diagnosed with angioedema of the small intestine — also known as intestinal angioedema, or sometimes angioedema of the bowel — related to the use of an angiotensin-converting enzyme (ACE) inhibitor to treat high blood pressure, according to…

Pendopharm has obtained the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat, an on-demand investigational treatment for hereditary angioedema (HAE), in Canada under a licensing agreement with Kalvista Pharmaceuticals, the developer of the therapy. “We look forward to collaborating with Pendopharm, whose deep…

In the years following treatment with the gene-editing therapy lonvoguran ziclumeran, or lonvo-z — also known as NTLA-2002 — most people with hereditary angioedema (HAE) taking part in a clinical trial have been completely free from swelling attacks without the need for long-term preventive therapy. That’s according to…

Navenibart, an experimental treatment from Astria Therapeutics to prevent swelling episodes in people with hereditary angioedema (HAE), continues to show strong and sustained benefits in a long-term clinical trial. New data from the ALPHA-SOLAR Phase 2 (NCT06007677) open-label extension study show treatment with navenibart every three…

Oral deucrictibant continued to control swelling attacks as a preventative therapy and rapidly stop swelling attacks as an on-demand treatment for hereditary angioedema (HAE), according to new data from the open-label extension portions of two clinical trials. All open-label extension participants said that preventive deucrictibant controlled their HAE…

The U.S. Food and Drug Administration (FDA) has approved Andembry (garadacimab-gxii) to prevent swelling attacks caused by hereditary angioedema (HAE) in adults and adolescents, ages 12 and older, adding the U.S. to the countries where the medication is available. Developed by CSL Behring, it’s the only treatment…

The oral medication Orladeyo (berotralstat) is now approved in Colombia as a preventive treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The approval, from Colombia’s National Institute of Drug and Food Surveillance (INVIMA), follows the therapy’s approval in…

Orladeyo is now approved for reimbursement in the Netherlands following a recommendation from healthcare government agency Zorginstituut Nederland. The treatment is used for routine prevention, or prophylaxis, of swelling attacks in people 12 years and older with hereditary angioedema (HAE). With this decision, Orladeyo…